BridgeBio Pharma is dedicated to developing breakthrough medicines for genetic diseases by bridging scientific advancements with commercial viability. The company focuses on treating underserved patient populations through innovative drug development and a commitment to fostering passionate, driven leaders in the field.
BridgeBio is seeking a Director of KOL Management & Engagement to lead a key opinion leader (KOL) engagement initiative for the ATTR-cardiomyopathy (ATTR-CM) portfolio. This role involves collaboration with key stakeholders, strategic planning, and execution to advance the commercial product pipeline, particularly within the US and global markets. The ideal candidate will demonstrate strong communication, leadership, and influence skills, contributing to both insights generation and fostering mutually beneficial partnerships.
BridgeBio Pharma is dedicated to developing breakthrough medicines for genetic diseases by bridging scientific advancements with commercial viability. The company focuses on treating underserved patient populations through innovative drug development and a commitment to fostering passionate, driven leaders in the field.